Persistent neutralising antibodies to interferon-beta and clinical outcomes in multiple sclerosis patients

被引：0
|
作者：
Costelloe, L. [1 ]
O'Rourke, K. [1 ]
Tubridy, N. [1 ]
Hutchinson, M. [1 ]
机构：
[1] St Vincents Univ Hosp, Dublin, Ireland
来源：
MULTIPLE SCLEROSIS | 2006年 / 12卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S205 / S205
页数：1
相关论文
共 50 条
  • [1] Interferon-beta neutralising antibodies in Canadian multiple sclerosis patients treated with different interferon-beta products
    Grossberg, S. E.
    Gehshan, A.
    Long, C.
    Chuppa, S. L.
    Nicholson, K.
    Grossberg, L. D.
    MULTIPLE SCLEROSIS, 2006, 12 : S207 - S208
  • [2] Frequency and clinical aspect of neutralising antibodies to interferon-beta in a large cohort of multiple sclerosis patients
    Bucello, S.
    Liberatore, G.
    Moiola, L.
    Radaelli, M.
    Sala, A.
    Capobianco, M.
    Bertolotto, A.
    Martinelli, V.
    Comi, G.
    MULTIPLE SCLEROSIS, 2009, 15 (09): : S130 - S130
  • [3] Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis
    Polman, Chris H.
    Bertolotto, Antonio
    Deisenhammer, Florian
    Giovannoni, Gavin
    Hartung, Hans-Peter
    Hemmer, Bernhard
    Killestein, Joep
    McFarland, Henry F.
    Oger, Joel
    Pachner, Andrew R.
    Petkau, John
    Reder, Anthony T.
    Reingold, Stephen C.
    Schellekens, Huub
    Sorensen, Per Soelberg
    LANCET NEUROLOGY, 2010, 9 (07): : 740 - 750
  • [4] NEUTRALISING ANTIBODIES TO INTERFERON-BETA PREDICT CONVERSION TO SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS IN PATIENTS WITH MULTIPLE SCLEROSIS
    Gafson, Arie
    Worthington, Viki
    Lakdawala, Neghat
    Giovannoni, Gavin
    Farrell, Rachel
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2013, 84 (11):
  • [5] Neutralising antibodies to interferon-beta therapy in relapsing multiple sclerosis: a pilot study
    Lau, A. Y. L.
    Chan, E.
    Lau, K. K.
    Mok, V
    Siu, D. Y. W.
    Lee, R.
    HONG KONG MEDICAL JOURNAL, 2019, 25 (04) : 22 - 25
  • [6] In vivo bioactivity of interferon-beta in multiple sclerosis patients with neutralising antibodies is titre-dependent
    Sominanda, A.
    Hillert, J.
    Fogdell-Hahn, A.
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2008, 79 (01): : 57 - 62
  • [7] Neutralising Antibodies to Interferon-beta Therapy in Chinese Patients with Relapsing and Remitting Multiple Sclerosis.
    Ip, W. K.
    Lau, A. Y. L.
    Zhang, S.
    Au, C. C. K.
    Wong, W.
    Lau, K. K.
    Li, P.
    Chan, E. Y. T.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 (03) : 416 - 417
  • [8] Correlation between anti-interferon-beta binding and neutralising antibodies in multiple sclerosis patients on interferon-beta therapy
    Jensen, P. E. H.
    Sellebjerg, F.
    Sondergaard, H. B.
    Sorensen, P. S.
    MULTIPLE SCLEROSIS JOURNAL, 2011, 17 : S120 - S120
  • [9] Antibodies to interferon-beta in patients with multiple sclerosis: Detection and clinical effects
    Sadiq, SA
    Revesz, KJ
    Lassman, AB
    Miller, JR
    NEUROLOGY, 1996, 46 (02) : 1073 - 1073
  • [10] Multiple sclerosis patients lacking antibodies in cerebrospinal fluid are less likely to develop neutralising antibodies against interferon-beta
    Lundqvist, M.
    Greiner, E.
    Imrell, K.
    Hillert, J.
    Fogdell-Hahn, A.
    MULTIPLE SCLEROSIS, 2009, 15 (09): : S19 - S20
12345